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Late proarrhythmia on sotalol therapy
triggered by emotional stress
Późny efekt proarytmiczny w trakcie terapii sotalolem
wywołany stresem emocjonalnym
Hanna Wachowiak−Baszyńska, Ewa Straburzyńska−Migaj, Romuald Ochotny, Stefan Grajek
1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
A b s t r a c t
We present a case of significant QTc prolongation with torsade de pointes in a female patient with a DDD pacemaker, who
had been treated with an established dose of sotalol for two years. The most probable trigger factor of this adverse event was
a strong emotional stress. The discontinuation of treatment with sotalol resulted in clinical recovery and QTc normalisation.
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INTRODUCTION
Sudden emotional stress may be connected with a transient
increase in catecholamine concentration, which in some in-
dividuals can have an unfavourable effect on the heart. We
present the case of a post-menopausal woman who expe-
rienced a significant late proarrhythmic adverse event during
sotalol treatment, in strict connection with strong emotional
stress, which caused a dramatic QTc prolongation with tor-
sade de pointes episodes, without any other signs of stress
cardiomyopathy.
CASE REPORT
A 71 year-old woman with systemic hypertension, type 2 dia-
betes mellitus, abdominal obesity and sick sinus syndrome
with paroxysmal atrial fibrillation, three years after the im-
plantation of a dual-chamber pacemaker, was admitted to
hospital because of recurrent pre-syncopal episodes, which
had started the previous evening shortly after extremely strong
emotional stress. For two years the patient had been taking
320 mg of sotalol daily for rhythm control as lower doses had
proved ineffective. Concomitant pharmacotherapy included
ramipril, losartan, indapamide, glimepiride and acenocuma-
rol with established doses of all the mentioned medications.
Electrocardiogram (ECG) on admission revealed paced rhy-
thm of 70 bpm with QTc prolongation to 666 ms, polymor-
phic ventricular extrasystoles with short runs of torsade de
pointes ventricular tachycardia (Figs. 1A, B). Her previous ECGs
from the pacemaker control centre showed only minor QTc
prolongation up to 475 ms (on the same dose of sotalol with
ventricular pacing) and there was no previous clinical eviden-
ce for ventricular arrhythmia. Laboratory tests on admission
excluded acute myocardial infarction, hypokaliemia or hy-
pomagnesaemia and kidney dysfunction. Echocardiography
revealed moderate eccentric hypertrophy of the left ventricle
(13 mm thickness of the interventricular septum and the po-
sterior wall), with impaired diastolic, but preserved systolic,
function with no regional diminished wall motion. Cessation
of treatment with sotalol, infusions with magnesium sulphate
and treatment with atenolol 100 mg daily resulted in a resolu-
tion of the symptoms. In two days, QTc decreased to 432 ms
and remained the same at a 14-day follow-up visit (Fig. 2).
DISCUSSION
Decisions regarding pharmacological prevention of atrial fi-
brillation must always be made after considering the risk of
side effects [1, 2]. Our patient, having metabolic syndrome,
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Figure 1A, B. Paced rhythm 70 bpm, with QTc prolongation to 666 ms, polymorphic ventricular extrasystoles with several short
runs of torsade de pointes ventricular tachycardia
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moderate left ventricle hypertrophy and a high risk of ischa-
emic heart disease, was not the ideal candidate for treatment
with sotalol. But this however seemed to be the best option.
Amiodarone was contraindicated in her case due to a history
of hyperthyroidism eight years previously, while propafeno-
ne had proved to be ineffective in the past and the patient
did not accept radiofrequency ablation. As she received a du-
al chamber pacing device, the risk of proarrhythmia due to
bradycardia was diminished [2] and treatment with sotalol
was introduced with a careful follow-up and QTc assessment
after each dosage increase, although because of ventricular
pacing we accepted QTc longer than 450 ms, but not exce-
eding 500 ms. The period of the highest risk of proarrhyth-
mia (the first three days of treatment [1, 2]) was uneventful.
Torsade de pointes appeared after strong emotional stress
(for two years the patient had been on the same medication
dose) and were related to significant prolongation of QTc
during paced rhythm. We found no trigger factor for this
adverse event other than mental stress. Significant QTc pro-
longation may be induced by a higher concentration of ca-
techolamines [3] and has been described in cases of phe-
ochromocytoma [4], strong emotional stress [5] and also in
patients with Tako-Tsubo syndrome [6]. Beta-adrenergic sti-
mulation has also been proved to induce early afterdepola-
risation in an animal model [3]. Female sex and left ventri-
cular hypertrophy are important risk factors for proarrhyth-
mia with sotalol [2], but this unusual case, featuring such
a late arrhythmic adverse event, could be caused by a sud-
den increase in sympathetic activity due to emotional stress.
Catecholamines may contribute to significant QT prolonga-
tion, resulting in torsade de pointes, especially in patients
with high risk of this arrhythmia:  not only with congenital
long QT syndrome, but also with prolonged QT interval se-
condary to pharmacological management.
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